Charles David Pauza - Apr 1, 2024 Form 4 Insider Report for Onconova Therapeutics, Inc. (TRAW)

Role: Chief Science Officer Virology
Signature: /s/ Charles David Pauza
Stock symbol: TRAW
Transactions as of: Apr 1, 2024
Transactions value $: $0
Form type: 4
Date filed: 4/3/2024, 08:04 PM

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	TRAW	Common Stock	Award		+97.5K			97.5K	Apr 1, 2024	Direct	F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	TRAW	Stock Option (right to purchase)	Award		+333K			333K	Apr 1, 2024	Common Stock	333K	$0.07	Direct	F2, F3
transaction	TRAW	Stock Option (right to purchase)	Award		+503K			503K	Apr 1, 2024	Common Stock	503K	$0.01	Direct	F2, F4

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	Represents an award of restricted stock units that will vest in four equal annual installments beginning April 1, 2025. Each restricted stock unit will convert into shares of common stock of Traws Pharma, Inc. (f/k/a Onconova Therapeutics, Inc., the "Company"), par value $0.01 per share ("Common Stock"), on a one-for-one basis.
F2	On April 1, 2024, the Company acquired Trawsfynydd Therapeutics, Inc. ("Trawsfynydd") in accordance with the terms of an Agreement and Plan of Merger, dated April 1, 2024 (the "Merger Agreement"), by and among the Company, Traws Merger Sub I, Inc., Traws Merger Sub II, LLC, and Trawsfynydd (the "Merger"). Upon consummation of the Merger, all of the outstanding shares of common stock of Trawsfynydd were converted into shares of Common Stock on a 1:20.1291 basis pursuant to the terms of the Merger Agreement.
F3	Received in the Merger in exchange for stock options to acquire 16,550 shares of Trawsfynydd common stock with an exercise price of $1.38 per share.
F4	Received in the Merger in exchange for stock options to acquire 25,000 shares of Trawsfynydd common stock with an exercise price of $0.0001 per share.